Breast cancer (early) - paclitaxel
Paclitaxel for the adjuvant treatment of early node-positive breast cancer
| Guidance type: Technology appraisal |
| Date issued: September 2006 |
We will consult on our review plans for this guidance in June 2007. |
| Reference: TA108 |
SummaryPaclitaxel is not recommended as an option for the adjuvant treatment of women with early node-postive breast cancer. Because Paclitaxel within its licensed indication is not recommended for the adjuvant treatment of women with early node-positive breast cancer then it is not considered to have any significant cost implications. Therefore, no costing template has been developed for this appraisal. |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the public
Background information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below:
|
| Top |
